ABS37: Add-on omalizumab improves asthma control across multiple measures of response in patients with severe persistent allergic (IgE-mediated) asthma

INTRODUCTION: Omalizumab is a novel anti-IgE therapy for patients having inadequately controlled severe persistent allergic asthma with uncontrolled symptoms despite GINA 2002 step 4 therapy (inhaled ICS + LABA∓ additional controller medication as necessary). Omalizumab reduces exacerbations in thes...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Prim Care Respir J
Hlavní autoři: Price, D., Fox, H., Ayre, G., Blogg, M., Massanari, M., Reisner, C.
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2006
Témata:
Abstracts
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6730752/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pcrj.2006.04.136
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky